| Item Type | Name |
|
Concept
|
Hypoglycemic Agents
|
|
Academic Article
|
Oral antidiabetic agents safe with renal disease?
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
|
Academic Article
|
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
|
|
Academic Article
|
The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance?
|
|
Academic Article
|
Effects of thiazolidinediones beyond glycaemic control.
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Metformin nephrotoxicity insights: will they change clinical management?
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
|
|
Academic Article
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
|
Academic Article
|
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
|
|
Academic Article
|
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
|
|
Academic Article
|
Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent.
|
|
Academic Article
|
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
|
|
Academic Article
|
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
|
|
Academic Article
|
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials.
|
|
Academic Article
|
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
|
|
Academic Article
|
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
|
|
Academic Article
|
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
|
|
Academic Article
|
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
|
|
Academic Article
|
SGLT2 Inhibitors and Mechanisms of Hypertension.
|
|
Academic Article
|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
|
|
Academic Article
|
Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
|
|
Academic Article
|
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
|
|
Academic Article
|
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
|
|
Academic Article
|
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
|
|
Academic Article
|
Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
|
|
Academic Article
|
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
|